In commercially available mouse and human primary caECs, we also observed robust cAMP responses to GLP-1(2836) (Figure 3B)
This is where Ipamorelin provides a critical counterbalance
The researchers used robust statistical methods, including inverse probability of treatment weighting to control for measured confounding
Implications for treatment and the future of personalized medicine This study underscores the need for including female subjects in pre-clinical studies, along with the potential of developing personalized dosing strategies for GLP-1 therapies
Any dietary changes should be implemented as part of a comprehensive management plan that includes regular monitoring of glycaemic control, weight, and treatment response
Cumulative tissue repair requires time, and early symptomatic improvements may underestimate the full potential of ongoing treatment